Abbott reported a 1% decline in its diagnostics segment sales to $2.17 billion in Q2 2025, impacted by a continued decrease in COVID-19 test volumes and China’s volume-based procurement program. CEO Robert Ford cited combined headwinds exceeding $1 billion, including reduced U.S. HIV test funding. Although the China core laboratory market delayed recovery until Q4, Abbott’s diagnostics outside China showed robust growth, with core labs rising 8% globally. The firm surpassed earnings estimates with $1.26 adjusted EPS and projects solid full-year organic sales growth excluding COVID-related testing.